Aggressive B-Cell Lymphoma
Aggressive B-Cell Lymphoma
The latest news, research, and perspectives in aggressive B-cell lymphoma. These fast-growing non-Hodgkin lymphomas, including diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma, arise at different stages of B-cell development.
Advertisement
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | March 23, 2023
Drs. Kambhampati and Thiruvengadam discuss their study investigating the cost effectiveness of pola-R-CHP in DLBCL.
Listen Now
Cecilia BrownAggressive B-Cell Lymphoma | March 22, 2023
Axicabtagene ciloleucel showed a significant improvement in OS over standard of care in relapsed or refractory LBCL.
Leah SherwoodAggressive B-Cell Lymphoma | March 16, 2023
ADX-2191 is a sterile, noncompounded intravitreal formulation of methotrexate.
Leah SherwoodAggressive B-Cell Lymphoma | March 10, 2023
The FDA is expected to make a final decision on the supplemental BLA for polatuzumab vedotin-piiq in DLBCL in early April.
Cecilia BrownViewpoints | February 28, 2023
Dr. Pickl discusses potential future uses and implications of a novel biomarker to predict responses to CAR-T in DLBCL.
Leah SherwoodAggressive B-Cell Lymphoma | February 27, 2023
AB-101 is an allogeneic, cryopreserved, ADCC-enhancing natural killer-cell therapy.
Advertisement
Cecilia BrownVideo Insights | February 22, 2023
Winfried F. Pickl, MD, discusses a novel biomarker that can predict CAR-T responses in patients with DLBCL.
Cecilia BrownTransplantation & Cellular Therapy | February 21, 2023
The study's investigators identified a four-gene model that segregated patients with different survival probabilities.
Leah SherwoodAcute Myeloid Leukemia | February 20, 2023
Advocates hope it will bring much-needed changes to patient care for complex cancers—including hematologic malignancies.
Cecilia BrownMeeting News | February 16, 2023
The estimated 24-month nonrelapse mortality was significantly lower in the CAR-T cohort than in the allogeneic HSCT cohort.
Leah SherwoodAggressive B-Cell Lymphoma | February 10, 2023
The results showed pembrolizumab was well tolerated, with 23.5% of patients achieving a complete response.
Laurie Sehn, MD, MPHAggressive B-Cell Lymphoma | February 7, 2023
Given the multitude of novel therapies recently approved, clinicians must consider how to best sequence the options.
Leah LawrenceAggressive B-Cell Lymphoma | February 7, 2023
CAR-T therapy leads to responses in most patients with aggressive B-cell lymphoma, but durable CRs only occur in a minority.
Leah SherwoodAggressive B-Cell Lymphoma | February 7, 2023
Glofitamab is an investigational CD20×CD3 T-cell-engaging bispecific antibody.
Michael Dickinson, MBBS, DMedSc, FRACP, FRACPAVideo Insights | January 20, 2023
Michael Dickinson, MBBS, DMedSc, discusses trials in progress that are evaluating glofitamab with other agents for DLBCL.
Michael Dickinson, MBBS, DMedSc, FRACP, FRACPAVideo Insights | January 18, 2023
Michael Dickinson, MBBS, DMedSc, discusses a phase II trial of glofitamab, a bispecific antibody, in patients with DLBCL.
Blood Cancers Today Staff WritersVideo Insights | January 17, 2023
The panel discusses new targets for DLBCL and FL and shares what excites them about the future for these diseases.
Blood Cancers Today Staff WritersVideo Insights | January 13, 2023
The panel discusses regulatory hurdles and patient access considerations for non-Hodgkin lymphoma therapies.
Michael Dickinson, MBBS, DMedSc, FRACP, FRACPAVideo Insights | January 13, 2023
Michael Dickinson, MBBS, DMedSc, discusses updates on glofitamab that were presented during the 2022 ASH meeting.
Cecilia BrownPrint | January 13, 2023
Survival outcomes are typically poor in patients with relapsed/refractory aggressive BCL who relapse after anti-CD19 CAR-T.
Advertisement
Advertisement
Editorial Board